# Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

> **NCT00820417** · PHASE1 · COMPLETED · sponsor: **Harrison Clinical Research** · enrollment: 63 (actual)

## Conditions studied

- Colorectal Cancer
- Head and Neck Cancer
- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Cetuximab/Gefitinib combination and/or monotherapy

## Key facts

- **NCT ID:** NCT00820417
- **Lead sponsor:** Harrison Clinical Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-09
- **Final completion:** 2008-05
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2009-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820417, "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00820417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*